Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Clinical trial NCT05206591 · WITHDRAWN
Trial details
- NCT number
- NCT05206591
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-16
- Primary completion
- 2028-03-20
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.